



# OPERATIVE OUTCOMES OF LAPAROSCOPIC SPLENECTOMY FOR MASSIVE VS MODERATE SPLENOMEGALY

Saksham Gagal, MBBS<sup>1</sup>; Manjunath M Pol, MS<sup>1</sup>; Brahma K Rath, MS, MCh<sup>2</sup>

<sup>1</sup>All India Institute Of Medical Sciences, New Delhi; <sup>2</sup>Institute of Medical Science and Sum Hospital, Bhubaneswar



## INTRODUCTION

For splenic disorders, Laparoscopic splenectomy (LS) is the gold standard, causing less pain, shorter hospital stay, and faster recovery.(1)

Laparoscopic approach for Massive splenomegaly (MS) remains technically challenging, but latest advancement have expanded feasibility of LS and this study compares outcomes of LS in Massive vs moderate splenomegaly.(2)

## MATERIALS AND METHODS

**STUDY DESIGN:** Retrospective cohort Study

**STUDY POPULATION:** All adult (18-65 years) patients who underwent elective Laparoscopic Splenectomy performed by a single surgeon

**Group I - Massive Splenomegaly (MS) Group (n=39)** comprised patients whose maximal splenic dimension exceeded 20 cm, or whose resected splenic specimen weight was greater than 1000g

**Group II - Patients** whose spleens did not meet the criteria were classified as the Moderate Splenomegaly Group (n=24)

**STUDY DURATION:** Between February 2024 and August 2025

**STUDY LOCATION:** Department of Surgical Disciplines, All India Institute of Medical Sciences (AIIMS), New Delhi.

### INCLUSION CRITERIA

Patients were selected by review of the department's electronic database and physical medical records

### EXCLUSION CRITERIA

Incomplete medical records.

Open splenectomy (No preselection considering spleen size except one patient who refused to consent to a Laparoscopic procedure.)

### STATISTICAL ANALYSIS

Descriptive and comparative statistics using appropriate parametric/non-parametric tests, with  $p < 0.05$  considered significant (Stata software).


## Perioperative care

Endoscopic Variceal Ligation for significant varices; Vaccination against pneumococcus, H. influenzae, and meningococcus.

Antibiotics perioperatively; Intermittent Pneumatic Compression device for all patients.

NG tube and Foley catheterization in all; No preoperative splenic artery embolization.

## Operative procedure



## RESULTS

| Total patients                                      | 63                       | Indication for splenectomy                             | Count (%)  |
|-----------------------------------------------------|--------------------------|--------------------------------------------------------|------------|
| Mean age (years)                                    | 32 ± 14                  | – Hereditary spherocytosis                             | 16 (25.4%) |
| Female                                              | 35 (55.6%)               | – NCPF (Non-cirrhotic portal fibrosis)                 | 19 (30.2%) |
| BMI (kg/m <sup>2</sup> )                            | 22.2 ± 2.9               | – Thalassemia                                          | 8 (12.7%)  |
| Cirrhosis (Child-Pugh), n (%)                       | A: 6 (9.5%); B: 1 (1.6%) | – EHPVO (Extra-hepatic portal vein obstruction)        | 7 (11.1%)  |
| Haemoglobin (g/dL), mean ± SD                       | 9.1 ± 2.1                | – CLD with portal hypertension                         | 1 (1.6%)   |
| Platelet count (×10 <sup>3</sup> /μL), median ± IQR | 86 (45-134)              | – Myeloproliferative neoplasm with portal hypertension | 2 (3.2%)   |
| History of Blood Transfusion, n (%):                | 41(65%)                  | – Splenic Hemangioma                                   | 2 (3.2%)   |
| Varices on endoscopy, n (%)                         | 17 (27.0%)               | – Others (Hydatid cyst, ITP, Gilbert Syndrome)         | 8 (14.3%)  |
| Concomitant shunt procedure, n (%)                  | 4 (6.3%)                 |                                                        |            |

|                                                     | Moderate (n=24) | Massive (n=39)   | p-value |
|-----------------------------------------------------|-----------------|------------------|---------|
| Clinical profile                                    |                 |                  |         |
| Portal hypertension, n (%)                          | 7 / 24 (29.2%)  | 27 / 39 (69.2%)  | 0.004   |
| Platelet count (×10 <sup>3</sup> /μL), median (IQR) | 132 (68.5-187)  | 73 (37-101)      | 0.01    |
| Intraoperative                                      |                 |                  |         |
| Collaterals, n (%)                                  | 6 / 24 (25%)    | 26 / 39 (66.6%)  | 0.001   |
| Adhesions, n (%)                                    | 7 / 24 (29.2%)  | 26 / 39 (66.6%)  | 0.003   |
| Operative time (min), mean ± SD                     | 142 ± 55        | 178 ± 56         | 0.01    |
| Blood loss (mL), median (range)                     | 80 (50-150)     | 200 (100-300)    | 0.001   |
| Intraoperative transfusion, n (%)                   | 6 / 24 (25.0%)  | 15 / 39 (38.5%)  | 0.27    |
| Conversion to open surgery, n (%)                   | 1 / 24 (4.2%)   | 1 / 39 (2.6%)    | 1.00    |
| Re-exploration for bleeding, n (%)                  | 1 / 24 (4.2%)   | 3 / 39 (7.7%)    | 1.00    |
| Postoperative                                       |                 |                  |         |
| Postoperative transfusion, n (%)                    | 2 / 24 (8.3%)   | 5 / 39 (12.8%)   | 0.58    |
| Any complication, n (%)                             | 6 / 24 (25.0%)  | 11 / 39 (28.2%)  | 0.78    |
| Clavien-Dindo Grade                                 |                 |                  |         |
| – Minor                                             | 5 / 24 (20.8%)  | 8 / 39 (20.5%)   | 0.97    |
| – Major (≥ III)                                     | 1 / 24 (4.2%)   | 3 / 39 (7.7%)    | 1.00    |
| Post-op length of stay (days), median (range)       | 2 (1-8)         | 2 (1-32)         | 0.32    |
| Spleen characteristics                              |                 |                  |         |
| Splenic vein diameter (mm), mean ± SD               | 11.1± 2.4       | 12.0 ± 2.2       | 0.16    |
| Portal vein diameter (mm), mean ± SD                | 13.5 ± 2.6      | 14.0 ± 2.2       | 0.40    |
| Maximum spleen size (cm), mean ± SD                 | 16.2 ± 3.1      | 23.6 ± 4.3       | 0.00    |
| Spleen weight (g), median (IQR)                     | 626 (538-812)   | 1081 (1000-1247) | 0.00    |

**Portal hypertension:** Presence of peri-splenic varices and extensive hilar collaterals increases operative difficulty and bleeding risk, meticulous intraoperative vascular control allows safe LS with acceptable morbidity.

|                                    | Portal Hypertension (n= 34) | Absent (n=29) | p-value |
|------------------------------------|-----------------------------|---------------|---------|
| Intraoperative                     |                             |               |         |
| Collaterals, n (%)                 | 31 (91.1%)                  | 1 (3.4%)      | 0.00    |
| Adhesions, n (%)                   | 28 (82.3%)                  | 5 (17.2%)     | 0.00    |
| Operative time (min), mean ± SD    | 180 +- 60                   | 146 +- 50     | 0.01    |
| Blood loss (mL), median (range)    | 200 (50-1700)               | 50 (15-800)   | 0.0001  |
| Intraoperative transfusion, n (%)  | 15 (44.1%)                  | 6 (20.6%)     | 0.049   |
| Conversion to open surgery, n (%)  | 2 (5.8 %)                   | 0             | -       |
| Re-exploration for bleeding, n (%) | 3 (8.8 %)                   | 1 (3.4%)      | 0.61    |
| Postoperative                      |                             |               |         |
| Postoperative transfusion, n (%)   | 5 (14.7%)                   | 2 (6.9%)      | 0.42    |
| Any complication, n (%)            | 11 (32.3%)                  | 6 (20.6%)     | 0.29    |

- Technical challenges:

Reduced working space, dense adhesions, and extensive collaterals increase bleeding risk (3)

- Outcomes in MS:

Even very large spleens (up to 30 cm, 4.6 kg) can be managed laparoscopically, and spleen size alone should not mandate open surgery.

- Key technical strategies

Optimized positioning, early arterial control, advanced energy devices, and postoperative thrombosis surveillance.

- Supermassive Splenomegaly (>1,600 g)

Six patients with specimen weights ranging from 1,676 g to 4,600 g (mean: 2,426g ± 1,082g)

- Spleno-Renal shunt

4 patients ; Small subcostal incision after laparoscopic splenic mobilization

## LIMITATIONS

- Retrospective single-center design, limited sample size, potential selection bias, and lack of long-term outcome analysis may affect generalizability.
- Future direction: Larger prospective multicentre studies are needed

## REFERENCES

- Misiakos EP, Bagias G, Liakakos T, Machairas A. Laparoscopic splenectomy: Current concepts. World J Gastrointest Endosc. 2017 Sep 16;9(9):428–37.
- Tsamalaidze L, Stauffer JA, Permenter SL, Asbun HJ. Laparoscopic Splenectomy for Massive Splenomegaly: Does Size Matter? J Laparoendosc Adv Surg Tech A. 2017 Oct;27(10):1009–14.
- Vecchio R, Milluzzo SM, Troina G, Cacciola E, Cacciola RR, Catalano RS, et al. Preoperative Predictive Factors of Conversions in Laparoscopic Splenectomies. Surg Laparosc Endosc Percutan Tech. 2018 Jun;28(3):e63–7.